Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -8.75
- Piotroski Score 1.00
- Grade N/A
- Symbol (ENOB)
- Company Enochian Biosciences, Inc.
- Price $0.71
- Changes Percentage (1.79%)
- Change $0.01
- Day Low $0.70
- Day High $0.75
- Year High $2.99
Enochian Biosciences, Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company's lead candidate includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-11, a preventative HIV vaccine; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a coopting HBV polymerase. Its pipeline development products comprise ENOB-DC-11 off the shelf DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intraturmoral injection. Enochian Biosciences, Inc. has strategic partnerships with The Scripps Institute, Fred Hutchinson Cancer Research Center, the Texas Biomedical Research Institute, the University of California, Los Angeles, and The Hepatitis B Foundation and Baruch S. Blumberg Institute. The company was incorporated in 2017 and is headquartered in Los Angeles, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/08/2023
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$2.07
- Trailing P/E Ratio -0.34420289855072
- Forward P/E Ratio -0.34420289855072
- P/E Growth -0.34420289855072
- Net Income $-80,650,171
Income Statement
Quarterly
Annual
Latest News of ENOB
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
'Xenoblade Chronicles X' Is Finally Coming To The Switch Next Year
Xenoblade Chronicles X is finally being ported to the Switch after initial doubts. The game's unique features, like giant mecha, posed challenges for porting. This marks one of the last Wii U exclusiv...
By Forbes | 1 month ago -
DeNobile's 2 TD passes in final minute rallies Lafayette to 40-35 win over Monmouth
Lafayette defeated Monmouth 40-35 with Dean DeNobile's late touchdowns. DeNobile threw for 394 yards and 2 TDs, with Elijah Steward making 15 catches for 244 yards. The game saw a total of 955 yards o...
By AP NEWS | 2 months ago